LncRNA MEG3 exacerbates diabetic cardiomyopathy via activating pyroptosis signaling pathway

Shengnan Zhuo1, Yifeng Liu2, Siyuan Wang1

  • 1School of Pharmacy, School of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, China.

PubMed

Insights

Long non-coding RNA MEG3 (lncMEG3) worsens diabetic cardiomyopathy by activating the NLRP3 inflammasome. Silencing lncMEG3 reduces inflammation and improves heart function in diabetic mice.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Diabetic cardiomyopathy (DCM) is a common complication of diabetes.
  • Long non-coding RNA maternally expressed gene 3 (lncMEG3) is implicated in heart conditions, but its role in DCM is unknown.

Purpose of the Study:

  • Investigate the role of lncMEG3 in DCM.
  • Elucidate the molecular mechanisms underlying lncMEG3's function in DCM.

Main Methods:

  • Established a diabetic mouse model using streptozotocin (STZ).
  • Used heart-targeted adeno-associated virus (AAV9-shMEG3) to silence lncMEG3.
  • Assessed cardiac function via echocardiography and cardiac remodeling via H&E and Masson trichrome staining.
  • Analyzed molecular mechanisms using Western blot and qPCR.

Main Results:

  • lncMEG3 expression was elevated in DCM hearts and high-glucose-treated cardiomyocytes.
  • lncMEG3 knockout improved cardiac function and reduced inflammation, fibrosis, and hypertrophy in diabetic mice.
  • lncMEG3 silencing inhibited NLRP3 inflammasome activation.
  • lncMEG3 acted as a sponge for miR-223, and miR-223 inhibition reversed the effects of lncMEG3 knockdown on NLRP3 inflammasome.

Conclusions:

  • lncMEG3 exacerbates DCM by promoting NLRP3 inflammasome activation.
  • This occurs via attenuation of miR-223-mediated NLRP3 degradation.
  • Targeting lncMEG3 may offer a therapeutic strategy for DCM.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K